Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic
AssigneeKrystal Biotech, Inc.
InventorsSuma Krishnan, Trevor Parry, Pooja Agarwal
Life of this patent
Estimating the term…
Abstract
The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding one or more cosmetic proteins (e.g., one or more human collagen proteins); viruses comprising the recombinant nucleic acids; compositions (e.g., cosmetic formulations) comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.
Claims14
A composition for topical, transdermal, superficial, or intradermal administration comprising:
- (a) a replication defective herpes simplex virus type 1 (HSV-1) comprising a recombinant HSV-1 genome, wherein the recombinant HSV-1 genome comprises a first polynucleotide encoding a first protein;
- and
- (b) an excipient;
- wherein the first protein is selected from the group consisting of a first collagen protein, a first fibronectin protein, a first elastin protein, a first lumican protein, a first vitronectin protein, a first vitronectin receptor protein, a first laminin protein, a first neuromodulator protein, and a first fibrillin protein,
- wherein the recombinant HSV-1 genome comprises an inactivating mutation in one or both copies of the Infected Cell Protein (ICP) 4 herpes simplex virus gene, and
- wherein the recombinant HSV-1 genome does not comprise a polynucleotide encoding a Collagen alpha-1 (VII) chain (COL7) polypeptide.
A method of improving skin condition, quality, and/or appearance in a subject, the method comprising administering to the subject an effective amount of a composition comprising:
- (a) a replication defective HSV-1 comprising a recombinant HSV-1 genome, wherein the recombinant HSV-1 genome comprises a first polynucleotide encoding a first protein;
- and
- (b) an excipient;
- wherein the first protein is selected from the group consisting of a first collagen protein, a first fibronectin protein, a first elastin protein, a first lumican protein, a first vitronectin protein, a first vitronectin receptor protein, a first laminin protein, a first neuromodulator protein, and a first fibrillin protein,
- wherein the recombinant HSV-1 genome comprises an inactivating mutation in one or both copies of the ICP4 herpes simplex virus gene,
- wherein the composition is administered topically, transdermally, intradermally, or via superficial injection to the subject, and
- wherein the recombinant HSV-1 genome does not comprise a polynucleotide encoding a COL7 polypeptide.
Dependencies are inferred from the claim text.